Grace Therapeutics, INC. (GRCE) — 8-K Filings

8-K Filings (18)

• Grace Therapeutics Files 8-K — Nov 13, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also inclu
• Grace Therapeutics Files 8-K — Oct 23, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. un
• Grace Therapeutics Files 8-K — Sep 18, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting on "Other Events" and "Financial Statements and Exhibits." The company, formerly known as
• Grace Therapeutics Files 8-K on Shareholder Matters — Sep 12, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on September 12, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Ac
• Grace Therapeutics Files 8-K — Aug 27, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on August 27, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc., is
• Grace Therapeutics Files 8-K — Jun 25, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on June 25, 2025, reporting on other events and financial statements. The company, formerly known as Acasti Pharma Inc. un
• Grace Therapeutics Files 8-K — Apr 9, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. until
• Grace Therapeutics Files 8-K — Mar 3, 2025 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on March 3, 2025, reporting on Other Events and Financial Statements and Exhibits. The company, formerly known as Acasti P
• Grace Therapeutics Files 8-K on Agreements and Equity Sales — Feb 10, 2025 Risk: medium
  Grace Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and other eve
• Grace Therapeutics Changes Fiscal Year End — Oct 28, 2024 Risk: low
  Grace Therapeutics, Inc. filed an 8-K on October 28, 2024, reporting a change in its fiscal year end to March 31. The company, formerly known as Acasti Pharma I
• Acasti Pharma Files 8-K — Oct 25, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on October 25, 2024, to report other events and financial statements. The filing does not contain specific details about the nat
• Acasti Pharma Enters Material Agreement, Modifies Security Holder Rights — Oct 7, 2024 Risk: medium
  Acasti Pharma Inc. announced on October 1, 2024, that it entered into a material definitive agreement. The company also made material modifications to the right
• Acasti Pharma Files 8-K: Director Changes & Shareholder Votes — Sep 30, 2024 Risk: medium
  Acasti Pharma Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. The fi
• Acasti Pharma Files 8-K — Sep 25, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on September 25, 2024, reporting other events and financial statements. The company, incorporated in Quebec with principal execu
• Acasti Pharma Relocates Principal Offices — Aug 16, 2024 Risk: low
  Acasti Pharma Inc. announced on August 12, 2024, a change in its principal executive offices to 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540. Th
• Acasti Pharma Files 8-K with Office and Contact Info — Jun 27, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The filing details the company's principal executive offices
• Acasti Pharma Files 8-K for Regulatory Disclosure — Apr 1, 2024 Risk: low
  Acasti Pharma Inc. filed an 8-K on April 1, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specif
• Acasti Pharma 8-K: Executive Comp & Leadership Changes — Jan 8, 2024
  Acasti Pharma Inc. filed an 8-K on January 5, 2024, to report changes in its executive compensation arrangements and potentially the departure or election of di

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX